Aldeyra Therapeutics Inc
Open
1.8 11.11
Overzicht
Wijziging aandelenprijs
24u
Min
1.62
Max
1.95
Inkomsten | -23T -3.5M |
|---|---|
EPS | -0.06 |
Werknemers | 7 |
EBITDA | 2.4M -3.5M |
Aanbevelingen | Buy |
|---|---|
12 Maanden Prognose | +237.42% upside |
Volgende Winsten | 5 aug 2026 |
|---|
Marktkapitalisatie | 2.4M 100M |
|---|---|
Vorige openingsprijs | -9.31 |
Vorige sluitingsprijs | 1.8 |
Aldeyra Therapeutics Inc Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
Aldeyra Therapeutics Inc Prognose
Koersdoel
By TipRanks
237.42% opwaarts potentieel
12 Maanden Prognose
Gemiddelde 5.5 USD 237.42%
Hoogste 9 USD
Laagste 2 USD
Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Aldeyra Therapeutics Inc - Dist. in de afgelopen 3 maanden.
Financieel
Verkoop- en administratiekosten
Bedrijfskosten
Winst voor belastingen
Verkoop
Kosten van verkopen
Brutowinst op verkopen
Rente-uitgaven op schulden
EBITDA
Operationele winst
$
Over Aldeyra Therapeutics Inc
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
